Cellules souche et Dérivés

Momelotinib sulfate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.

MRK-560 is an effective and brain-penetrant inhibitor of γ-secretase.

FzM1.8: allosteric FZD4 agonist, pEC50=6.4; boosts TCF/LEF, activates WNT/β-catenin with no WNT needed.

JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in

Neurodazine is a neural inducer that promotes the differentiation of pluripotent cells into neuronal cells.

QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following

GSK-3β Inhibitor 19 (compound 36) is an inhibitor of GSK-3β with an IC50 value of 70 nM. It is applicable in research related to anti-inflammatory and Alzheimer's disease.

PI-828 (LY 294002), a PI3K inhibitor, researches PI3K function and aids stem cell differentiation into mesoderm.

SGC-CK2-1, a CK2 inhibitor, is a inducer of insulin production and secretion in pancreatic β-cells.

CK1-IN-2 (compound Nr.4) is a potent inhibitor of CK1, exhibiting IC50 values of 123 nM for CK1a, 19.8 nM for CK1d, 26.8 nM for CK1e, and 74.3 nM for p38a [1].

Stafib-1 is a selective inhibitor of STAT5β targeting SH2 domain with an IC50 of 154 nM and a Ki of 44 nM.

YAP/TAZ-TEAD-IN-2 (Compound 51) is a YAP/TAZ-TEAD inhibitor that disrupts the interaction between YAP/TAZ and TEAD. It inhibits the transcriptional activity of TEAD with an IC50 of 1.2 nM. Additionally, YAP/TAZ-TEAD-IN-2 suppresses the expression of target genes (Cyr61, CTGF, AXL, and Survivin) and the proliferation of breast cancer cells.

JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.

PF-06952229 is a selective inhibitor of TGFβRI. PF-06952229 can be used in studies about the treatment of solid tumors, specifically metastatic breast cancer.

TEAD-IN-2 is a potent and bifunctional TEAD inhibitor to induce TEAD protein degradation via the ubiquitination pathway, with anticancer potential.

Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).

MRT-83 is a potent Smo antagonist.

Solcitinib (GLPG-0778), a JAK1 inhibitor, may treat psoriasis, ulcerative colitis, and lupus.

Galunisertib (LY2157299) is a selective TGF-β receptor type I (TGF-βRI) inhibitor. Galunisertib has antitumor activity. Cost-effective and quality-assured.

"Casein kinase 1δ-IN-4 (compound 567) is a potent inhibitor of casein kinase 1δ with potential application in Alzheimer's disease research [1]."

Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.

JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].

JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.

SB-772077B dihydrochloride is an aminofurazan-based Rho kinase inhibitor (IC50s: 5.6 nM and 6 nM toward ROCK1 and ROCK2, respectively).

P17 Peptide, a human TGF-β1 inhibitory peptide, effectively blocks the activity of woodchuck TGF-β1.

Nefopam hydrochloride (Nefopam HCl) is the hydrochloride salt form of nefopam, a centrally-acting, non-opioid benzoxazocine with analgesic activity.

Vantictumab (OMP-18R5) is a humanized anti-FZD1/2/5/7/8 monoclonal antibody that inhibits Wnt pathway signaling.

STAT3HiBiT degrader 1 is a potent degrader of STAT3HiBiT, exhibiting a DC50 of less than 0.05 μM in A549 cells.

JK184 is a potent Hedgehog (Hh) pathway inhibitor.

TINK-IN-1 is a selective and potent TNIK inhibitor (IC50: 8 nM).TINK-IN-1 inhibits colorectal cancer cell viability and can be used to study mental retardation.

Fresolimumab (GC1008) is a human monoclonal antibody targeting active TGFβ1, TGFβ2, TGFβ3, studied for cancer and focal segmental glomerulosclerosis.

TAK-441: oral Hedgehog signal blocker, potent anticancer, IC50=4.4 nM, reduces Gli1 mRNA & tumor growth.

β-catenin/CBP-IN-1 is a potent and selective inhibitor of CBP/β-catenin

Chroman 1 is a potent inhibitor of ROCK1 (IC50 = 52 pM) and ROCK2 (IC50 = 1 pM).

AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).

β-catenin-IN-2 is a potent inhibitor of β-catenin that can be used in colorectal cancer research.

KY02111 facilitates differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, maybe affect downstream of GSK3β and APC.

Avagacestat (BMS-708163) (BMS-708163) is a potent, selective, orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM,

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Simian OC/BGP. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Simian OC/BGP. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Simian OC/BGP, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Simian OC/BGP in the samples is then determined by comparing the OD of the samples to the standard curve.

WAY-297174 is a human protein kinase CK2 inhibitor with IC50 of > 33 μM.

GSK-3β inhibitor 8 (GSK3β Inhibitor XVIII) is a potent and selective GSK-3β inhibitor with an IC50 value of 64 nM.GSK-3β inhibitor 8 is a thienopyrimidine

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.

AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor.

GSK-3 inhibitor 3 is a selective, orally active, brain-permeable GSK-3 inhibitor that inhibits GSK-3α and GSK-3β with IC50s of 0.35 nM and 0.25 nM, respectively

YAP-TEAD-IN-3 inhibitor YAP/TAZ-TEAD interactions Avi-human TEAD (4217-434) YAP-TEAD-IN-3 inhibits YAP reporter gene expression and NCI-H2052 cell proliferation

GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).

VT104 is a potent and orally active YAP/TAZ inhibitor for cancer research.Cost-effective and quality-assured.

AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.

RKI1313 (RKI-1313) was a selective inhibitor for ROCK-dependent signaling, cytoskeletal changes, anchorage-independent colony formation, migration, and invasion

A 1070722: potent GSK-3 inhibitor, Ki = 0.6 nM for both α/β isoforms, crosses BBB, potential brain GSK-3 PET radiotracer.